Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum β-lactamases

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 5, 2017, Pages

  Haidar, Ghady ^a   Clancy, Cornelius J ^a,b,c   Shields, Ryan K ^a,b   Hao, Binghua ^a   Cheng, Shaoji ^b   Nguyen, M Hong ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Ceftazidime avibactam; Drug resistance mechanisms; KPC; Site directed mutagenesis

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; BETA LACTAMASE KPC 3; CEFEPIME; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFTAROLINE; CEFTAZIDIME; CEFTRIAXONE; CLAVULANIC ACID; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BACTERIAL PROTEIN; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; BETA-LACTAMASE KPC-3, KLEBSIELLA PNEUMONIAE; CARBAPENEM DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM MUTANT; CONTROLLED STUDY; DISK DIFFUSION; EPSILOMETER TEST; ESCHERICHIA COLI; EXPRESSION VECTOR; GENE MUTATION; GENETIC VARIABILITY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DRUG EFFECTS; GENETICS; HUMAN; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTERIAL PROTEINS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CARBAPENEMS; CEFTAZIDIME; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MUTAGENESIS, SITE-DIRECTED;

EID: 85018158691     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02534-16     Document Type: Article

References (26)

1. Haidar G, Alkroud A, Cheng S, Churilla TM, Churilla BM, Shields RK, Doi Y, Clancy CJ, Nguyen MH. 2016. Association between the presence of aminoglycoside-modifying enzymes and in vitro activity of gentamicin, tobramycin, amikacin, and plazomicin against Klebsiella pneumoniae carbapenemase-and extended-spectrum-beta-lactamase-producing Enterobacter species. Antimicrob Agents Chemother 60:5208-5214. https://doi. org/10. 1128/AAC. 00869-16.
2. Ahn C, Syed A, Hu F, O'Hara JA, Rivera JI, Doi Y. 2014. Microbiological features of KPC-producing Enterobacter isolates identified in a U. S. hospital system. Diagn Microbiol Infect Dis 80:154-158. https://doi. org/10. 1016/j. diagmicrobio. 2014. 06. 010.
3. Centers for Disease Control and Prevention. FAQs about choosing and implementing a CRE definition. Centers for Disease Control and Prevention, Atlanta, GA. https://www. cdc. gov/hai/organisms/cre/definition. html.
4. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y. 2012. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 56: 2108-2113. https://doi. org/10. 1128/AAC. 06268-11.
5. Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL. 2014. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 20:862-872. https://doi. org/10. 1111/1469-0691. 12697.
6. Forest Pharmaceuticals, Inc. 2016. Avycaz (ceftazidime-avibactam) prescribing information. Forest Pharmaceuticals, Inc., Cincinnati, OH.
7. Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, Press EG, Kreiswirth BN, Clancy CJ, Nguyen MH. 2016. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 63:1615-1618. https://doi. org/10. 1093/cid/ciw636.
8. Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, Pandey R, Doi Y, Kreiswirth BN, Nguyen MH, Clancy CJ. 28 December 2016. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother https://doi. org/ 10. 1128/AAC. 02097-16.
9. Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing; 25th informational supplement. CLSI M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Livermore DM, Warner M, Jamrozy D, Mushtaq S, Nichols WW, Mustafa N, Woodford N. 2015. In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. Antimicrob Agents Chemother 59:5324-5330. https://doi. org/10. 1128/AAC. 00678-15.
11. Winkler ML, Papp-Wallace KM, Bonomo RA. 2015. Activity of ceftazidime/ avibactam against isogenic strains of Escherichia coli containing KPC and SHV beta-lactamases with single amino acid substitutions in the omegaloop. J Antimicrob Chemother 70:2279-2286. https://doi. org/10. 1093/ jac/dkv094.
12. Levitt PS, Papp-Wallace KM, Taracila MA, Hujer AM, Winkler ML, Smith KM, Xu Y, Harris ME, Bonomo RA. 2012. Exploring the role of a conserved class A residue in the omega-loop of KPC-2 beta-lactamase: A mechanism for ceftazidime hydrolysis. J Biol Chem 287:31783-31793. https:// doi. org/10. 1074/jbc. M112. 348540.
13. Wolter DJ, Kurpiel PM, Woodford N, Palepou MF, Goering RV, Hanson ND. 2009. Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. Antimicrob Agents Chemother 53:557-562. https://doi. org/10. 1128/AAC. 00734-08.
14. Paterson DL, Bonomo RA. 2005. Extended-spectrum beta-lactamases: A clinical update. Clin Microbiol Rev 18:657-686. https://doi. org/10. 1128/ CMR. 18. 4. 657-686. 2005.
15. Bush K, Jacoby GA. 2010. Updated functional classification of betalactamases. Antimicrob Agents Chemother 54:969-976. https://doi. org/ 10. 1128/AAC. 01009-09.
16. Giske CG, Sundsfjord AS, Kahlmeter G, Woodford N, Nordmann P, Paterson DL, Canton R, Walsh TR. 2009. Redefining extended-spectrum beta-lactamases: balancing science and clinical need. J Antimicrob Chemother 63:1-4. https://doi. org/10. 1093/jac/dkn444.
17. Rupp ME, Fey PD. 2003. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs 63:353-365. https://doi. org/10. 2165/ 00003495-200363040-00002.
18. Livermore DM. 2008. Defining an extended-spectrum beta-lactamase. Clin Microbiol Infect 14(Suppl):S3-S10. https://doi. org/10. 1111/j. 1469-0691. 2007. 01857. x.
19. Lee CH, Su LH, Tang YF, Liu JW. 2006. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: A retrospective study and laboratory analysis of the isolates. J Antimicrob Chemother 58:1074-1077. https://doi. org/10. 1093/jac/dkl381.
20. Harris PN, Tambyah PA, Paterson DL. 2015. Beta-lactam and betalactamase inhibitor combinations in the treatment of extendedspectrum beta-lactamase producing Enterobacteriaceae: Time for a reappraisal in the era of few antibiotic options Lancet Infect Dis 15:475-485. https://doi. org/10. 1016/S1473-3099(14)70950-8.
21. Retamar P, Lopez-Cerero L, Muniain MA, Pascual A, Rodriguez-Bano J, ESBL-REIPI/GEIH Group. 2013. Impact of the MIC of piperacillintazobactam on the outcome of patients with bacteremia due to extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 57:3402-3404. https://doi. org/10. 1128/AAC. 00135-13.
22. Stachyra T, Levasseur P, Pechereau MC, Girard AM, Claudon M, Miossec C, Black MT. 2009. In vitro activity of the-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J Antimicrob Chemother 64:326-329. https://doi. org/ 10. 1093/jac/dkp197.
23. Perez F, Bonomo RA. 2015. Editorial commentary: bloodstream infection caused by extended-spectrum beta-lactamase-producing Gramnegative bacteria: how to define the best treatment regimen Clin Infect Dis 60:1326-1329.
24. Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, Avdic E, Cosgrove SE, Antibacterial Resistance Leadership Group. 2015. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum betalactamase bacteremia. Clin Infect Dis 60:1319-1325.
25. Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A, Extended-Spectrum Beta-Lactamases-Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria Group. 2012. Betalactam/ beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: A post hoc analysis of prospective cohorts. Clin Infect Dis 54: 167-174. https://doi. org/10. 1093/cid/cir790.
26. Perez F, Bonomo RA. 2012. Can we really use beta-lactam/betalactamase inhibitor combinations for the treatment of infections caused by extended-spectrum beta-lactamase-producing bacteria Clin Infect Dis 54:175-177. https://doi. org/10. 1093/cid/cir793.